title: Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.
abstract: BACKGROUND
  70-80% of sporadic endometrial carcinomas are defined as endometrioid carcinoma (EC). Early-stage, well differentiated endometrial carcinomas usually retain expression of estrogen and progesterone receptors (ER and PR, respectively), as advanced stage, poorly differentiated tumors often lack one or both of these receptors. Well-described EC prognosis includes tumor characteristics, such as depth of myometrial invasion. Therefore, in the current study, we evaluated the expression profile of ER and PR isoforms, including ER-α, PR-A and PR-B, in correlation to EC tumor histological depth.
  
  
  METHODS
  Using immunohistochemistry and image analysis software, the expression of ER-α, PR-A, PR-B and Ki67 was assessed in endometrial stroma and epithelial glands of superficial, deep and extra-tumoral sections of 15 paraffin embedded EC specimens, and compared to 5 biopsies of non-malignant endometrium.
  
  
  RESULTS
  Expression of PR-A and ER-α was found to be lower in EC compared to nonmalignant tissue, as the stromal expression was dramatically reduced compared to epithelial cells. Expression ratios of both receptors were significantly high in superficial and deep portions of EC; in non-tumoral portion of EC were close to the ratios of nonmalignant endometrium. PR-B expression was low in epithelial glands of EC superficial and deep portions, and high in the extra-tumoral region. Elevated PR-B expression was found in stroma of EC, as well.
  
  
  CONCLUSIONS
  The ratio of ER-α and PR-A expression in the epithelial glands and the stroma of EC biopsies may serve as an additional parameter in the histological evaluation of EC tumor.
  The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1155060506119016.
authors.forename: Hila
authors.initials: H
authors.lastname: Kreizman-Shefer
authors.forename: Jana
authors.initials: J
authors.lastname: Pricop
authors.forename: Shlomit
authors.initials: S
authors.lastname: Goldman
authors.forename: Irit
authors.initials: I
authors.lastname: Elmalah
authors.affiliation: Laboratory for Research in Reproductive Sciences and Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel. shaleve@technion.ac.il.
authors.forename: Eliezer
authors.initials: E
authors.lastname: Shalev
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D018269:Carcinoma, Endometrioid / Q000737:chemistry* / Q000473:pathology; D016889:Endometrial Neoplasms / Q000737:chemistry* / Q000473:pathology; D004847:Epithelial Cells / Q000737:chemistry / Q000473:pathology; D047628:Estrogen Receptor alpha / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D020033:Protein Isoforms; D011980:Receptors, Progesterone / Q000032:analysis*; D017154:Stromal Cells / Q000737:chemistry / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D019394:Ki-67 Antigen; D020033:Protein Isoforms; D011980:Receptors, Progesterone; C101118:progesterone receptor A; C097314:progesterone receptor B